Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer

被引:52
作者
Wong, Mark
Balleine, Rosemary L.
Blair, Elaine Y. L.
McLachlan, Andrew J.
Ackland, Stephen P.
Garg, MadhuB.
Evans, Scott
Farlow, David
Collins, Michael
Rivory, Laurent P.
Hoskins, Janelle M.
Mann, Graham J.
Clarke, Christine L.
Gurney, Howard
机构
[1] Westmead Inst Canc Res Westmead Millennium Inst, Dept Translat Oncol, Sydney, NSW, Australia
[2] Westmead Inst Canc Res Westmead Millennium Inst, Dept Nucl Med, Sydney, NSW, Australia
[3] Westmead Inst Canc Res Westmead Millennium Inst, Dept Med Oncol, Sydney, NSW, Australia
[4] Inst Clin Pathol & Med Res, Westmead, NSW, Australia
[5] Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia
[6] Univ Sydney, Dept Pharmacol, Sydney, NSW 2006, Australia
[7] Univ Sydney, Dept Med, Sydney, NSW 2006, Australia
[8] Univ Sydney, Fac Med, Sydney, NSW 2006, Australia
[9] Newcastle Mater Misericordiae Hosp, Dept Med Oncol, Waratah, Australia
关键词
D O I
10.1200/JCO.2005.02.1295
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Marked interindividual variation in drug disposition and toxicity pose an ongoing challenge to chemotherapy dosage individualization. The aim of this study was to evaluate pretreatment clinical features, genotype and functional indicators of drug clearance as predictors of vinorelbine clearance, and myelotoxicity that could inform dosage optimization. Patients and Methods Forty-one patients with cancer received a 60 mg intravenous dose of vinorelbine. Pretreatment routine body size measurements and blood tests were performed. Midazolam clearance and hepatic technetium labeled sestamibi (Tc-99m-MIBI) clearance were used to investigate CYP3A and ABCB1 (MDR1, P-glycoprotein) phenotype respectively and selected single nucleotide polymorphisms in CYP3A and ABCB1 were documented. A limited blood sampling strategy was employed and vinorelbine concentrations were determined by high-performance liquid chromatography. Posterior Bayesian estimates of vinorelbine clearance were obtained for each patient using population pharmacokinetic modeling. Myelotoxicity was estimated from the fractional survival of neutrophils post-treatment. Results There was 4.3-fold variation in vinorelbine clearance across the cohort. In a multivariable analysis, pretreatment estimated creatinine clearance (P < .01) and hepatic Tc-99m-MIBI clearance (P = .01) were independent predictors of vinorelbine clearance. Fractional survival of neutrophils ranged from 1.3% to 100% and was significantly correlated with vinorelbine clearance (P < .01). Body-surface area was the only pretreatment predictor of fractional survival of neutrophils independent of vinorelbine clearance (P = .02). Conclusion Specific indicators of drug clearance provide predictive information about vinorelbine pharmacokinetics, and body-surface area, probably reflecting normal bone marrow reserve, provides an additional pharmacodynamic indicator. Use of a fixed dose of vinorelbine with modifications guided by pretreatment measures is worthy of prospective evaluation.
引用
收藏
页码:2448 / 2455
页数:8
相关论文
共 32 条
[1]   P-GLYCOPROTEIN MEDIATED RESISTANCE TO 5'-NOR-ANHYDRO-VINBLASTINE (NAVELBINE(R)) [J].
ADAMS, DJ ;
KNICK, VC .
INVESTIGATIONAL NEW DRUGS, 1995, 13 (01) :13-21
[2]  
BURRIS HA, 1994, SEMIN ONCOL, V21, P14
[3]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[4]   Causes for increased myelosuppression with increasing age in patients with oesophageal cancer treated by chemoradiotherapy [J].
Denham, JW ;
Ackland, SP ;
Burmeister, B ;
Walpole, E ;
Lamb, DS ;
Dady, P ;
Spry, NA .
EUROPEAN JOURNAL OF CANCER, 1999, 35 (06) :921-927
[5]  
DUBOIS D, 1989, NUTRITION, V5, P303
[6]   Dosing strategies for anticancer drugs: the good, the bad and body-surface area [J].
Felici, A ;
Verweij, J ;
Sparreboom, A .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (13) :1677-1684
[7]   Blood and plasma pharmacokinetics of vinorelbine in elderly patients with advanced metastatic cancer [J].
Gauvin, A ;
Pinguet, F ;
Culine, S ;
Astre, C ;
Cupissol, D ;
Bressolle, F .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 49 (01) :48-56
[8]   A limited-sampling strategy to estimate individual pharmacokinetic parameters of vinorelbine in elderly patients with advanced metastatic cancer [J].
Gauvin, A ;
Pinguet, F ;
Culine, S ;
Astre, C ;
Gomeni, R ;
Bressolle, F .
ANTI-CANCER DRUGS, 2002, 13 (05) :473-480
[9]  
GOMENI R, 1994, ANTICANCER RES, V14, P2321
[10]   Multidrug resistance in cancer: Role of ATP-dependent transporters [J].
Gottesman, MM ;
Fojo, T ;
Bates, SE .
NATURE REVIEWS CANCER, 2002, 2 (01) :48-58